An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease

Annals of Pharmacotherapy

Volumn 43, Issue 9, 2009, Pages 1426-1432

  Stoner, Steven C ^a   Dahmen, Megan M ^b   Makos, Mignon ^c   Lea, Jessica W ^d   Carver, Lora J ^e   Rasu, Rafia S ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b Christi Regional Medical Center   (United States)

^c St Joseph Neurology   (United States)

^d MedTrak Pharmacy Services   (United States)

^e Walgreen's Pharmacy   (United States)

Author keywords

Dopamine; Parkinson's disease; Psychosis; Restless legs syndrome; Ropinirole

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; ROPINIROLE;

AGED; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DATA BASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RESTLESS LEGS SYNDROME;

AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DOPAMINE AGONISTS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; OUTPATIENTS; PARKINSON DISEASE; PSYCHOSES, SUBSTANCE-INDUCED; RESTLESS LEGS SYNDROME; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 69949087420     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M183     Document Type: Article

References (23)

1. Poewe W. Treatments for Parkinson disease - past achievements and current clnical needs. Neurology 2009;72(suppl 2):S65-73.
2. Winkelman JW, Allen RP, Tenzer P, Hening W. Restless legs syndrome: nonpharmacologic and pharmacologic treatments. Geriatrics 2007;62:13-16 (Pubitemid 47614549)
3. Perea EP, Robbins BV, Hutto B. Psychosis related to ropinirole. Am J Psychiatry 2006;163:546-547
4. Singh A. Althoff R, Marineau RJ, Jacobson J. Pramipexole, ropinirole, and mania in Parkinson's disease (letter). Am J Psychiatry 2005;162:814-815 (Pubitemid 40489160)
5. Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005;50:357-360 (Pubitemid 43175517)
6. Sethi KD, O'Brien CF, Hammerstad JP, et al. Ropinirole for the treatment of early Parkinson disease. Arch Neurol 1998;55:1211-1216
7. Rascol O, Brooks DJ, Korczyn AD, De Deyn, PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491 (Pubitemid 30318272)
8. Patient information sheet. Requip (ropinirole). Research Triangle Park, NC: GlaxoSmithKline Pharmaceuticals, July 2008.
9. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998;51:1057-1062 (Pubitemid 28473400)
10. Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY. Ropinirole in the treatment of patients with restless leg syndrome: a US based randomized, double-blind, placebo-controlled clinical trial. Mayo Clinic Proc 2006;81:17-27. (Pubitemid 43054313)
11. Walters AS, Ondo WG, Dreyfkluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19:1414-1423 (Pubitemid 38526058)
12. Montplaisir J, Karrasch J, Haan J, Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord 2006;21:1627-1635 (Pubitemid 44742190)
13. Chen JJ, Pahwa R. Pharmacologic management of Parkinson disease: choice of initial therapy in early disease. J Pharm Pract 2008;21:244-253 (Pubitemid 352019956)
14. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-745 (Pubitemid 30162723)
15. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson's disease. Arch Neurol 1996;53:1265-1268 (Pubitemid 26425072)
16. Zahonde LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease. Drugs Aging 2008;25:665-682
17. Hubble JP. Long-term studies of dopamine agonists. Neurology 2002;58(suppl 1):S42-50.
18. Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 1997;49(suppl 1):S58-62.
19. BowenWP, Coldwell MC, Hicks FR, Riley GJ, Fears R. Ropinirole, a novel dopaminergic agent for the treatment of Parkinson's disease, with selectivity for cloned dopamine D3 receptors (abstract). Br J Pharmacol 1993;110(proc suppl October):93P.
20. Fears R, Bowen WP, Brown F, et al. The novel dopaminergic agent ropinirole selectively binds to cloned dopamine D3 receptors (abstract). Can J Neurol Sci 1993;20(suppl 4):S68.
21. Jost WH, Angersbach D. Ropinirole, a non-ergoline dopamine agonist. CNS Drug Rev 2005;11:253-272
22. Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf 2003;26:439-444 (Pubitemid 36560715)
23. Li CT, Tsai SJ, Hwang JP. Pramipexole induced psychosis in Parkinson's disease (letter). Psychiatry Clin Neurosci 2008;62:245.